Literature DB >> 9329624

Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.

E Eigenbrodt1, D Basenau, S Holthusen, S Mazurek, G Fischer.   

Abstract

Proliferating and tumor cells express a certain isoenzyme of pyruvate kinase, called PK type M2. This isoenzyme can be isolated in an active tetrameric and an inactive dimeric form. We have termed this form tumor type M2-PK. This tumor type pyruvate kinase can be quantified by a specific ELISA in blood sera and tumor homogenates. In this study we have compared 26 normal colon mucosa and colon cancer specimens from the same patients. The total specific pyruvate kinase activity and the amount of the tumour type M2-PK measured by ELISA was increased in the tumor samples compared to the normal colon mucosa of the same patient. In normal colon mucosa the specific PK-activity ranged between 0.21 and 1.25 U/mg protein whereas in colon carcinoma we found activities between 0.99 and 7.08 U/mg. The amount of tumor M2-PK measured by ELISA ranged between 0.82 and 27.10 U/mg protein in normal colon mucosa and between 1.96 and 242.40 U/mg protein in colon carcinoma. The tumor M2-PK content in the serum of 666 healthy blood donors was measured by ELISA and compared to sera from 15 colon carcinoma patients and showed a highly significant difference (Mann-Whitney rank sum test, p < 0.001). The values for the 50%-percentiles (median) of blood donors were 10.8 U/ml and 55.0 U/ml for colon carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329624

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  27 in total

1.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Jian-kang Jiang; Matthew B Boxer; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2010-04-11       Impact factor: 2.823

2.  Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence.

Authors:  Werner Zwerschke; Sybille Mazurek; Petra Stöckl; Eveline Hütter; Erich Eigenbrodt; Pidder Jansen-Dürr
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

3.  Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.

Authors:  Anastasiya Vladimirovna Snezhkina; George Sergeevich Krasnov; Andrew Rostislavovich Zaretsky; Alex Zhavoronkov; Kirill Mikhailovich Nyushko; Alexey Alexandrovich Moskalev; Irina Yurievna Karpova; Anastasiya Isaevna Afremova; Anastasiya Valerievna Lipatova; Dmitriy Vladimitovich Kochetkov; Maria Sergeena Fedorova; Nadezhda Nikolaevna Volchenko; Asiya Fayazovna Sadritdinova; Nataliya Vladimirovna Melnikova; Dmitry Vladimirovich Sidorov; Anatoly Yurievich Popov; Dmitry Valerievich Kalinin; Andrey Dmitrievich Kaprin; Boris Yakovlevich Alekseev; Alexey Alexandrovich Dmitriev; Anna Viktorovna Kudryavtseva
Journal:  BMC Genomics       Date:  2016-12-28       Impact factor: 3.969

4.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

Review 5.  Glucose metabolism in gastric cancer: The cutting-edge.

Authors:  Lian-Wen Yuan; Hiroharu Yamashita; Yasuyuki Seto
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

6.  Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.

Authors:  Jiangbin Ye; Anthony Mancuso; Xuemei Tong; Patrick S Ward; Jing Fan; Joshua D Rabinowitz; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

7.  Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.

Authors:  J Roigas; S Deger; J Schroeder; A Wille; I Turk; B Brux; K Jung; D Schnorr; S A Loening
Journal:  Urol Res       Date:  2003-09-26

8.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia.

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Abdulkader Albasri; Mohammad Ilyas; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.